In the BioHarmony Drug Report Database
Genosyl, Inomax, INOmax (nitric oxide) is a small molecule pharmaceutical. Nitric oxide was first approved as Genosyl on 1999-12-23. It is used to treat newborn respiratory distress syndrome in the USA. It has been approved in Europe to treat pulmonary hypertension and respiratory insufficiency. It is known to target potassium channel subfamily K member 17 and potassium channel subfamily K member 16. Inomax’s patents are valid until 2036-05-03 (FDA).
Image (chem structure or protein)